Sarepta Therapeutics (NASDAQ:SRPT) Sets New 1-Year Low – Should You Sell?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares hit a new 52-week low on Tuesday . The company traded as low as $98.82 and last traded at $99.69, with a volume of 1639059 shares changing hands. The stock had previously closed at $103.03.

Analyst Ratings Changes

SRPT has been the topic of a number of research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They set a “hold” rating and a $136.00 price objective on the stock. Piper Sandler dropped their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. HC Wainwright reissued a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $170.41.

Sarepta Therapeutics Stock Performance

The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm’s 50-day moving average is $112.83 and its two-hundred day moving average is $120.55. The stock has a market cap of $9.68 billion, a price-to-earnings ratio of 79.82 and a beta of 0.79.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Sarepta Therapeutics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock valued at $1,104,701,000 after acquiring an additional 117,904 shares during the last quarter. Capital International Investors raised its holdings in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares during the last quarter. Farallon Capital Management LLC raised its holdings in Sarepta Therapeutics by 11.1% in the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after acquiring an additional 285,100 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after acquiring an additional 665,087 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.